Literature DB >> 11788626

Cross-sectional and prospective associations between abdominal adiposity and proinsulin concentration.

Anthony J G Hanley1, Gail McKeown-Eyssen, Stewart B Harris, Robert A Hegele, Thomas M S Wolever, Jeremy Kwan, Bernard Zinman.   

Abstract

The objective of this study was to investigate the associations of total and abdominal obesity with variation in proinsulin concentration in a Native Canadian population experiencing an epidemic of type 2 diabetes mellitus (DM). Between 1993 and 1995, 728 members of a Native Canadian community participated in a population-based survey to determine the prevalence and risk factors for type 2 DM. Samples for glucose, C-peptide, and proinsulin were drawn after an overnight fast, and a 75-g oral glucose tolerance test was administered. Type 2 DM and impaired glucose tolerance (IGT) were diagnosed using World Health Organization criteria. Height, weight, waist circumference, and percent body fat were measured. In 1998, 95 individuals who, at baseline, had IGT or normal glucose tolerance with an elevated 2-h glucose level (> or = 7.0 mM) participated in a follow-up evaluation using the same protocol. After adjustment for age, sex, C-peptide concentration, per cent body fat, and waist circumference, proinsulin was found to be significantly elevated in diabetic subjects, relative to subjects with both impaired and normal glucose tolerance (both P < 0.0001); and the concentration in those with IGT was higher, compared with normals (P < 0.0001). Among nondiabetic subjects, proinsulin showed significant univariate associations with percent body fat, body mass index, and waist circumference (r = 0.34, 0.45, 0.41, respectively, all P < 0.0001). After adjustment for body fat and other covariates, waist circumference remained significantly associated with proinsulin concentration in nondiabetic subjects (r = 0.20, P < 0.0001). In prospective analysis, adjusted for covariates (including baseline IGT and follow-up glucose tolerance status), baseline waist circumference was positively associated with both follow-up and change in proinsulin concentration (r = 0.27, P = 0.01; r = 0.24, P = 0.03, respectively). These data highlight the detrimental effects of abdominal obesity on beta-cell function, and support the hypothesis that beta-cell dysfunction occurs early in the natural history of glucose intolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788626     DOI: 10.1210/jcem.87.1.8139

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Influence of obesity on the risk of developing colon cancer.

Authors:  E E Frezza; M S Wachtel; M Chiriva-Internati
Journal:  Gut       Date:  2005-10-20       Impact factor: 23.059

2.  Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study.

Authors:  Mingyang Song; Frank B Hu; Donna Spiegelman; Andrew T Chan; Kana Wu; Shuji Ogino; Charles S Fuchs; Walter C Willett; Edward L Giovannucci
Journal:  Int J Epidemiol       Date:  2015-09-24       Impact factor: 7.196

3.  Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa.

Authors:  Adriana C Vidal; Pauline Kay Lund; Cathrine Hoyo; Joseph Galanko; Lauren Burcal; Rachel Holston; Berri Massa; Oluwaseun Omofoye; Robert S Sandler; Temitope O Keku
Journal:  BMC Cancer       Date:  2012-09-05       Impact factor: 4.430

4.  The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study.

Authors:  Sebastiao Freitas de Medeiros; Laura Camila Antunes Angelo; Matheus Antonio Souto de Medeiros; Camila Regis Banhara; Bruna Barcelo Barbosa; Marcia Marly Winck Yamamoto
Journal:  J Clin Med Res       Date:  2018-01-26

5.  Is the nuclear factor kappa-b (NF-κB) pathway and inflammatory status associated with colorectal cancer?

Authors:  Büşra Atabilen; Gamze Akbulut; Merve Bacanli; Doğan Uncu
Journal:  Saudi J Gastroenterol       Date:  2022 Jan-Feb       Impact factor: 2.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.